Seda Kahraman

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci et al. · BMC Cancer · 2023 · 23 citations · Full text

The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study

Elvina Almuradova, Mustafa Seyyar, Hacı Arak et al. · International Journal of Cancer · 2023 · 22 citations · Full text

Urology, Radiation Medicine, Lu-177 Psma-617 Rlt +13

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Seda Kahraman, Enes Erul, Mustafa Seyyar et al. · Future Oncology · 2023 · 21 citations · Full text

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabıyev et al. · The Breast · 2022 · 19 citations · Full text

Cyclin-dependent Kinase 4–6, Breast Oncology, Oncology +9

Association of serum betatrophin with fibroblast growth factor-21 in women with polycystic ovary syndrome

Seda Kahraman, Özlem Gülbahar, Burak Arslan et al. · Journal of Endocrinological Investigation · 2018 · 15 citations

Serum Betatrophin, Human Growth, Fibroblast Growth Factor-21 +9